# Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Source: https://onco.cc/trials/nct05877430/  
OnCo record `nct05877430` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab in melanoma and metastatic cancer, run by CJ Bioscience, Inc., now recruiting.

## Summary

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer is a phase 1/2 interventional study registered as NCT05877430 by CJ Bioscience, Inc., with 160 participants planned, started 2023-09-11 and due to reach its primary completion in 2026-07. Interventions recorded: CJRB-101, Pembrolizumab injection. Conditions listed: NSCLC, HNSCC, Melanoma, Metastatic Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05877430
- Phase: 1/2
- Setting: Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
- Sponsor: CJ Bioscience, Inc.
- Enrolled: 160

## Sources

- ClinicalTrials.gov NCT05877430: https://clinicaltrials.gov/study/NCT05877430

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct05877430.json